Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates

Company Performance - Acadia Pharmaceuticals reported quarterly earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.10 per share, and showing an increase from $0.10 per share a year ago, representing a 10% earnings surprise [1] - The company posted revenues of $244.32 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.23%, and up from $205.83 million year-over-year [2] - Over the last four quarters, Acadia has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Acadia shares have declined approximately 20.8% since the beginning of the year, compared to a 4.7% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.18 on revenues of $262.31 million, and for the current fiscal year, it is $0.68 on revenues of $1.06 billion [7] - The estimate revisions trend for Acadia is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Acadia belongs, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]